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Abstract
Background: microRNAs (miRNAs) are small single-stranded non-coding RNAs that act as crucial regulators of gene 
expression. Different methods have been developed for miRNA expression profiling in order to better understand gene 
regulation in normal and pathological conditions. miRNAs expression values obtained from large scale methodologies 
such as microarrays still need a validation step with alternative technologies.
Results: Here we have applied with an innovative approach, the Luminex® xMAP™ technology validate expression data 
of differentially expressed miRNAs obtained from high throughput arrays. We have developed a novel labeling system 
of small RNA molecules (below 200 nt), optimizing the sensitive cloning method for miRNAs, termed miRNA 
amplification profiling (mRAP). The Luminex expression patterns of three miRNAs (miR-23a, miR-27a and miR-199a) in 
seven different cell lines have been validated by TaqMan miRNA assay. In all cases, bead-based meas were confirmed 
by the data obtained by TaqMan and microarray technologies.
Conclusions: We demonstrate that the measure of individual miRNA by the bead-based method is feasible, high 
speed, sensitive and low cost. The Luminex® xMAP™ technology also provides flexibility, since the central reaction can 
be scaled up with additional miRNA capturing beads, allowing validation of many differentially expressed miRNAs 
obtained from microarrays in a single experiment. We propose this technology as an alternative method to qRT-PCR for 
validating miRNAs expression data obtained with high-throughput technologies.
Background
MicroRNAs (miRNAs) are endogenous 18-24 nucleotides
(nt) long noncoding RNAs (ncRNA) that control gene
expression by targeting mRNAs and triggering either
translation repression or degradation. The degree of
complementarity between a miRNA and its mRNA target
determines, at least in part, the regulatory mechanism
[1]. Recently, a third less understood mechanism of small
RNAs interference on gene expression involves hetero-
chromatin silencing [2]. Many miRNAs are highly con-
served among animals and plants [3] and it is estimated
that up to 33% of all mRNA coding genes are negatively
regulated by miRNAs [4,5]. miRNAs exhibit temporally
and spatially regulated expression patterns during diverse
developmental and physiological processes and clearly
animals cannot survive without miRNAs [6,7]. Most of
the miRNAs that have been characterized so far in ani-
mals seem to regulate developmental processes, includ-
ing larval stage transitions and neuronal development in
C. elegans [8], growth control and apoptosis in Droso-
phila melanogaster [9] or haematopoietic differentiation
in mammals. Many miRNAs have been found to display
unique tissue [10], developmental stage [11] or disease-
specific patterns [12]. These observations imply that each
tissue is characterized by a specific set of miRNAs that
contribute to the definition of the features of that tissue.
Hundreds of novel conserved and non-conserved
microRNAs have been identified by bioinformatic analy-
ses, suggesting that the total number of human miRNAs
could reach 1,000 [13]. According to recent computa-
tional predictions, as many as 200 mRNAs can be regu-
lated by a single miRNA, which implies that over one
third of protein-coding genes in humans are regulated by
miRNA [14,15].
So, the ability to monitor changes in miRNAs expres-
sion is important for understanding gene regulation both
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in physiological and pathological conditions. Several
methodologies have been adapted for profiling miRNA
expression: northern blotting with radiolabeled probes
[16,17], cloning [18,19], massive parallel signature
sequencing (MPSS) [20], quantitative PCR-based amplifi-
cation of precursor [21] or mature miRNAs [22], SAGE-
based techniques [23], bead-based profiling methods
[24,25] and oligonucleotide microarray [26]. Microarray
technology has been successfully used for evaluating vari-
ations of miRNA expression during development [27,28],
differentiation [29], oncogenesis [30-32], disease progres-
sion [33,34] and for the primary identification of new
miRNAs that were predicted by bioinformatic
approaches [35,36]. However, at present, no standard
methodology exists for hybridization-based profiling of
miRNAs and, as a consequence, comparison of expres-
sion data from different experiments can be difficult. To
solve these problems it will be necessary to develop qual-
ity procedures for miRNA microarrays. Furthermore,
miRNA expression obtained from high throughput arrays
has to be validated with alternative technologies. Quanti-
tative real-time PCR (qRT-PCR) has become the golden
standard of miRNA quantification because it offers the
highest sensitivity from small amounts of starting mate-
r i a l  a n d  i t  i s  a b l e  t o  d e t e c t  a s  l e s s  a s  1 - n t  d i f f e r e n c e
between miRNAs. Another interesting method is the
Luminex® x M A P ™  s y s t e m  t h a t  i s  a  m u l t i p l e x e d  m i c r o -
sphere-based suspension array platform capable of per-
forming and reporting up to 100 different analyses in a
single reaction vessel [37,38]. In particular, oligonucle-
otide-capturing probes complementary to miRNAs of
interest are coupled to carboxilated 5-micron polystirene
beads impregnated with variable mixtures of two fluores-
cent dyes, each representing a single miRNA. Using this
technique Lu and colleagues [24] were able to differenti-
ate tumours that were instead inaccurately classified by
mRNA profiles. Recently, a study performed with
Luminex miRNA platform, identified new markers of
human breast cancer subtype [39]. When compared to
glass-slide microarrays, the bead-based miRNA arrays
s h o w  m a n y  a d v a n t a g e s  s u c h  a s  e a s y  o f  u s e ,  l o w  c o s t ,
superior statistical performance, faster hybridization
kinetics (solution hybridization) and higher flexibility in
array preparation. Furthermore, the Luminex bead array
system has been used in a wide range of multianalyte
applications throughout the drug discovery and diagnos-
tics fields and it is also widely adopted for quantitative
multiplexed protein expression analysis [40,41].
In this study we have applied the Luminex® xMAP™
technology in a novel approach to validate expression
data of differentially expressed miRNAs obtained from
high throughput arrays. We have developed an innovative
system for labeling of small RNA molecules (below 200
nt) optimizing the sensitive cloning method for miRNAs,
termed mRAP, developed by Takada and Mano to define
mouse miRNA transcriptional signature [19,42,43]. The
expression patterns of three miRNAs (miR-23a, miR-27a
and miR-199a) measured by our Luminex approach in
seven different cell lines were validated by TaqMan
miRNA assay. In all cases, the two technologies gave
super imposable results. Our data demonstrate that bead-
based detection of individual miRNA is a feasible
approach, associated to high speed and low cost. The
Luminex® xMAP™ technology is also feasible for multi-
plexing, since several beads prepared to capture different
miRNAs can be added in the same reaction allowing the
validation of many differentially expressed miRNAs
obtained from large-scale approaches in a single experi-
ment.
Results and Discussion
miRNA expression in rhabdomyosarcoma cell lines
Rhabdomyosarcomas (RMS) are rare but very aggressive
tumours of childhood that arise as a consequence of reg-
ulatory disruption of the growth and differentiation path-
ways of myogenic precursor cells [44]. Based on
morphology, two major RMS subtypes can be identified:
embryonal RMS (ERMS) and alveolar (ARMS). To better
understand the global function of miRNA in RMS, we
analyzed the expression profile of 7 different RMS cell
lines (3 ARMS and 4 ERMS) using the mirVana miRNA
Probe Set V1 (Ambion) that is a collection of about 400
amino-modified DNA oligonucleotides [45]. Briefly, the
miRNA population from a single cell line was compared
to a reference sample consisting of a pool of the seven
small RNA samples ( < 200 nt) mixed in equal amounts.
The miRNA microarray platform was able to distinguish
PAX3-FKHR  positive (RH4, RH30) and negative RMS
(RD, CCA, SMS-CTR, RH36, RH18) cell lines through
the expression pattern of about 120 miRNAs (data not
shown). Since the translocation positive RMS patients
fared worse than the negative counterpart [46] our results
demonstrated the potential of miRNA expression profil-
ing to classify different RMS subtypes, in agreement to
previous gene expression studies [47-49], and set the
basis for a further functional characterization of selected
miRNAs implicated in RMS pathogenesis and in the dif-
ferent clinical behaviour and aggressiveness of the two
RMS subtypes. We decided to study miRNAs with the
greatest difference in expression between PAX3-FKHR
positive and negative RMS. So expression levels for three
discriminant miRNAs (miR-23a, miR-27a and miR-199a)
were validated by xMAP™ technology and TaqMan qRT-
PCR.
Testing the hybridization specificity and sensitivity 
between targets and capture probes coupled to 
microspheres
To prepare the capture probes, 21-23 bases-long oligonu-
cleotides with sequence complementary to each of theBiscontin et al. BMC Molecular Biology 2010, 11:44
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three differentially expressed miRNAs (miR-23a, miR-27a
and miR-199a) in RMS cell lines, were synthesized and
coupled to different color-coded microspheres in sepa-
rate reaction tubes and then mixed for multiplexed
assays. The targets were oligonucleotides complementary
to capture probes and tagged with biotin at their 5'-end.
Capture probes (approximately 5,000 beads for each
probe) were mixed in the same tube with targets at vari-
ous amounts ranging from 15 amol to 300 fmol. Phyco-
erythrin (PE)-coniugated streptavidin was added to the
reaction mixture to detect bound targets that were bioty-
nilated. The signal of each target hybridized to its specific
capture probe coupled to microspheres was determined
by the fluorescence intensity of phycoerytrin. At least 100
microspheres of each set were analyzed by the Bio-Plex™
system to obtain a median fluorescence intensity value
(MFI) that was representative of the whole population of
each set of beads. As shown in Figure 1A, the hybridiza-
tion signal for miR-199a with capture probe varied with
the amounts of added target in a logarithmic trend,
reaching a plateau when the targets were present at the
highest concentrations. Furthermore, the specificity of
hybridization did not change while increasing from 1 to 3
the number of different microspheres in the reaction. We
have evaluated the stability of conjugated microspheres at
regular intervals during 80 days after conjugation. The
hybridization signal is stable up to 35 days. As shown in
Figure 1A, the hybridization signal for the miR-199a
slightly decreased with the distance from conjugation,
but the hybridization between the capture probe and the
corresponding target remained specific and proportional.
Furthermore, our data show that it is better to use micro-
spheres conjugated in the same day to correctly detect
miRNA expression values. We have also represented the
curve in a log-scale (Figure 1B) highlighting the linearity
range of our technique: the lower limit of sensitivity is
0.073 fmol and the upper is 18.75 fmol. We have obtained
comparable results with either miR-23a or miR-27a. We
measured the specificity of our technique by testing the
variation in hybridization signal intensity when miR-27a
and miR-199a are captured with probes that contain one
or two mismatches in their complementary sequences
(see Table 1). We have evaluated the signal of each target
(biotynilated oligonucleotides perfectly complementary
to mature miRNA sequence) hybridized to the corre-
spondent capture probes with perfect match, one or two
mismatches. As described above, capture probes were
mixed in the same tube with targets at various amounts
(from 15 amol to 300 fmol). Figure 2 shows that for both
miRNAs we obtain a significant decrease of hybridization
fluorescence intensity with capture probes containing a
single mismatch. The signal drop is even greater with two
mismatches: 62% for miR-27a and 85% for miR-199a.
We have also determined the expression levels of above
cited miRNAs, using the capture probes with perfect
match, one or two mismatches in complex RNA popula-
tions obtained from seven RMS cell lines (RD, CCA,
SMS-CTR, RH36, RH18, RH4, RH30) in comparison to a
reference sample (Pool). As shown in Figure 3, we
observe a decreasing trend in fluorescence signal for the
capture probes with two mismatches. These experiments
show that the specificity of a capture probe is propor-
tional to the number of mismatches present in its
sequence and that this specificity guarantee the correct
q u a n t i f i c a t i o n  o f  m i R N A  e x p r e s s i o n  l e v e l s  i n  c o m p l e x
RNA populations.
A new application of mRAP method for miRNA labeling
We have developed a new sensitive miRNA labeling
method based on the mRAP strategy recently developed
by Mano and Takada for miRNA cloning [40,41]. This
new procedure is described schematically in Figure 4.
Small RNA molecules ( < 200-nt) purified by PureLink™
miRNA Isolation Kit (Invitrogen) were polyadenylated
with Poly(A) polymerase (PAP). Complementary DNAs
corresponding to the miRNAs were then synthesized
with the use of reverse transcriptase and a RT primer,
named Oligo-dT15-T7, complementary to the poly(A)
sequences added to the miRNA. This RT reaction was
allowed for 30 minutes in order to synthesize cDNA mol-
ecules of about 200 nt. We have used a degenerated
oligo(dT) to reduce the length of the neo-synthesized
poly(A) tails to 15 nucleotides. Given that some reverse
transcriptases possess terminal deoxynucleotidyl trans-
ferase activity, the synthesized cDNA strands frequently
result with small poly(C) overhangs at their 3' ends. After
annealing a long 5'-adptor, named SMART-16attB1-T3,
to such poly(C) overhangs, PCR was used to amplify the
miRNA-derived cDNAs. Using a T3-biotinylated forward
primer, we have obtained biotinylated cDNA that was
detected with Phycoerythrin (PE)-coniugated streptavi-
din after hybridization reaction. Every step of this proto-
col was quality checked by Agilent Bioanalyzer 2100 and
the resulting electropherograms are represented in Figure
4. Electropherogram analysis of the RT products have
revealed two major bands of ~30 and ~40 nt that corre-
spond to the 5'-adaptor (SMART-16attB1-T3) and the
oligo-dT15-T7 primer respectively. The electrophero-
grams also evidence the action of degenerated oligo(dT)
that reduces the length of neo-synthesized cDNAs to
100-110 nucleotides by shortening the poly(A) to 15 nt
(Figure 4).
We have decided to block PCR reaction during the
exponential phase at 22 cycles, to avoid distortion of the
actual concentration of miRNAs in the sample under
consideration. We have demonstrated that PCR cycles
between 20 and 25 are sufficient to achieve a good level ofBiscontin et al. BMC Molecular Biology 2010, 11:44
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Figure 1 Stability of conjugated microspheres and sensitivity of hybridization. A) Increasing amounts of miR-199a target oligonucleotide (from 
15 amol to 300 fmol) show higher fluorescence levels reaching a plateau when the target is present at high concentrations. The curve shows a loga-
rithmic trend. We observed a slightly decrease of the hybridization signal at 50, 65 and 80 days after conjugation. B) Calibration curve (0-35 days) of 
miR-199a in a log-scale from 15 amol to 300 fmol. The two lines show the linear and plateau range of fluorescence levels representing by two different 
slopes: 0.94 and 0.15 respectively with R2 = 0.99. The linearity range of our technique is comprised between a lower value of 0.073 fmol and an upper 
value of 18.75 fmol. Mean value of expression and 95% confidence intervals are associated to each fluorescence value (MFI corresponds to Median 
Fluorescence Intensity).Biscontin et al. BMC Molecular Biology 2010, 11:44
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amplification without reaching the plateau phase in
which the expression differences would be invalidated
(Figure 5A).
Finally, to verify the presence of miRNAs within the
labeled cDNA population we have identified, by PCR,
three specific miRNAs (miR-1, miR-206 and miR-450)
using the sequence of each miRNA as forward primer,
and the sequence for T7 promoter, which is common to
all labeled molecules, as reverse primer. The result of
PCR amplification of the three miRNAs is shown in Fig-
ure 5B.
Validation of differentially expressed miRNAs by Luminex® 
xMAP™ technology
Using the xMAP™ assay described above we have deter-
mined the expression levels of miR-23a, miR-27a and
miR-199a in seven RMS cell lines (RD, CCA, SMS-CTR,
RH36, RH18, RH4, RH30) in comparison to a reference
sample consisting of a pool of small RNA from each cell
line mixed in equal amounts.
To evaluate the validity and feasibility of an assay, it is
necessary to compare data with that obtained by other
established technologies such as, in this case, microarray
and qRT-PCR. As shown in Figure 6, the trends of expres-
sion levels measured for all the miRNAs by the three
technologies (microarray, xMAP™ and qRT-PCR) were
ve ry s im ila r .  Alt hou gh t he  a ct ua l  va lues  of  t he  r e la t ive
miRNA hybridization signals in the seven RMS cell lines
were not exactly the same for the three technologies, up-
regulated miRNAs (miR-23a and miR-27a) in PAX3-
FKHR positive RMS samples (RH4, RH30) detected origi-
nally by microarray were also up-regulated as detected by
xMAP™ and qRT-PCR, and signals for miRNAs down-
regulated in PAX3-FKHR  negative RMS samples (RD,
CCA, SMS-CTR, RH36, RH18) resulted consistently low
by all three independent technologies. To better under-
stand which are the techniques that provide the most
similar results we have applied non-parametric Spearman
correlation to the following paired comparisons for each
tested miRNAs: xMAPTM  vs. microarray, xMAPTM  vs.
qRT-PCR and qRT-PCR vs. microarray. It is interesting to
note that data obtained with xMAP™ technology seem to
be more similar to those defined by microarray (Spear-
man correlation: miR-199a = 0.64, miR-23a = 0.64, miR-
27a = 0.84) respect to qRT-PCR (Spearman correlation:
miR-199a = 0.67, miR-23a = 0.53, miR-27a = 0.81). From
this comparison we could observe that the PCR amplifi-
cation step introduced in xMAP™ labeling method does
not affect miRNA expression levels whereas miRNA
expression data obtained from < 200-nt RNA molecules
Table 1: Capture probes
ID Nucleotide sequence (5'-3') Lenght (nt)
miR-23a GGAAATCCCTGGCAATGTGAT 21
miR-27a GCGGAACTTAGCCACTGTGAA 21
miR-27a-1MM GCGGAACTAAGCCACTGTGAA 21
miR-27a-2MM GCGGAAGTTAGCCACTGAGAA 21
miR-199a GAACAGGTAGTCTGAACACTGGG 23
miR-199a-1MM GAACAGGTAGTCTGAAGACTGGG 23
miR-199a-2MM GATCAGGTAGTGTGAACACTGGG 23
Spike 18 CATTGCCACAATCAAGACTAAGA 23
Nucleotide sequence of capture probes synthesized with 5'-amino linker and a C12 spacer. Basepair mismatches (named MM) are in bold and 
underlined
Figure 2 Specificity of hybridization between capture probes and 
miRNA targets. Biotynilated miR-199a and miR27a (bottom panel) 
were captured in solution by the corresponding probes with exactly 
matching sequences (light grey boxes) or with one (dark grey boxes) 
or two mismatched bases (black boxes). The fluorescence signal ob-
tained by the hybridization of both the perfectly matching probes was 
set to 100%. The hybridization signal between both capture probes 
and the corresponding miRNA target shows a statistically significant 
decrease (p-value < 0.05) when one or two mismatches are introduced 
into the capture sequence. Hybridization experiments were obtained 
with 18.75 fmol of biotynilated targets that fall in the linearity range of 
our method as shown in Figure 1B. Mean value of expression and 95% 
confidence intervals are associated to each fluorescence value (%MFI 
corresponds to the percentage of Median Fluorescence Intensity).Biscontin et al. BMC Molecular Biology 2010, 11:44
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(microarray and xMAP™) differ slightly from those
obtained from total RNA (qRT-PCR). This is particularly
evident by non-parametric Spearman correlation for
qRT-PCR  vs. microarray (miR-199a = 0.94, miR-23a =
0.42, miR-27a = 0.70) with the exception of miR-199a.
Conclusions
We have described a new method that makes use of
xMAP™ technology for the quantitative determination of
single miRNAs. This approach quantifies miRNA expres-
sion levels based on hybridization of small RNA popula-
Figure 3 Specificity of hybridization between capture probes and miRNA targets in complex RNA populations. miR-199a (top panel) and 
miR27a (bottom panel) were captured from labeled total RNA populations prepared from 7 different RMS cell lines (RD, SMS-CTR, RH18, RH36, CCA, 
RH4, RH30) and a pool these RNA preparations mixed in equal amounts (POOL) with capture probes with exactly matching sequences (light grey box-
es) or with one (dark grey boxes) or two mismatched bases (black boxes). The hybridization signal in all complex RNA mixtures between both capture 
probes and the corresponding miRNA target in comparison to the reference pooled sample shows a statistically significant decrease (p-value < 0.05) 
when one or two mismatches are introduced into the capture sequence. Mean value of expression and 95% confidence intervals are associated to 
each fluorescence value (normalized MFI represents the average of the ratio between the value of fluorescence of miRNAs and the spike).Biscontin et al. BMC Molecular Biology 2010, 11:44
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Figure 4 Schematic representation of miRNA labeling method for bead based quantification. All protocol steps and quality checking with Ag-
ilent Bioanalyzer 2100 and gel electrophoresis (2% agarose) are schematically represented: starting material (RNA < 200 nt), the result of polyadeny-
lation reaction with PAP, the synthesis of first-strand cDNA (peaks are associated to Oligo-dT15-T7 and SMART-16attB1-T3 primers) and the second-
strand synthesis by PCR amplification.Biscontin et al. BMC Molecular Biology 2010, 11:44
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tions to the probes designed for miRNAs of interest that
are coupled to different color-coded microspheres. A
flow-cytometer is used to simultaneously measure the
hybridization signal associated with the surface of the
microspheres and to categorize the color-coded micro-
spheres. The method allows to obtain up to 100 indepen-
dent measures. This xMAP™ method offers affordable
cost, speed, and high flexibility with capability for multi-
plexed assays that are increasingly needed. It is valuable
for applications such as diagnostic detection of disease
miRNAs from clinical samples and validation of differen-
tially expressed miRNAs obtained from microarray anal-
ysis.
We have evaluated the stability of conjugated micro-
spheres demonstrating that they are stable for about one
month. We have also tested the specificity of hybridiza-
tion between targets and capture probes showing that the
introduction of a single mismatch in the sequence of cap-
ture probes significantly hampers its hybridization capac-
ity (Figures 2 and 3). These data have demonstrated the
specificity of our capture probes to correctly identify and
quantify the expression levels of miRNAs. We have devel-
oped a new sensitive small RNAs labeling protocol intro-
ducing some changes on mRAP strategy for miRNA
cloning. This protocol has been applied successfully to
validate the expression levels of three miRNAs that were
found differentially expressed in positive and negative
PAX3/FKHR alveolar rhabomyosarcomas by microarray
experiments. To demonstrate the reliability of this
method, the transcriptional levels of these miRNAs were
also determined by qRT-PCR with TaqMan probes. The
most significant information which emerges comparing
the data obtained by the three different technologies
(microarray, xMAP™ and qRT-PCR) is represented by the
general overlapping of the expression profiles obtained. It
is interesting to note that small differences in miRNAs
expression data could depend on the approaches used for
total RNA purification rather than on different labeling
protocols. In fact, microarray and xMAP™ data obtained
from labeling < 200-nt RNA molecules, are more similar
compared to qRT-PCR data obtained from labeling total
RNA, as demonstrated by the Spearman non parametric
correlation.
We think that the xMAP™ technology associated with
our new labeling protocol could become an alternative
and equally reliable method in the study of expression of
a limited number of miRNAs respect to qRT-PCR with
TaqMan probes. The comparison of the two experimen-
tal approaches (see Table 2) shows that the xMAP™ tech-
nique is less expensive and more flexible allowing the
simultaneous analysis of a larger number of miRNAs
from the same sample. In addition, xMAP™ does not need
for specific reverse transcription reactions for each
miRNA and provides at least 100 independent measures
for each miRNA, improving the statistical power. More-
over, xMAP™ expression data can be normalized respect
to a spike fluorescence signal added in known quantities
in the early stages of the labeling reaction, allowing the
control over all stages of the reaction. In this way there is
n o  n e e d  o f  a n  e n d o g e n o u s  c o n t r o l ,  l i k e  i n  q R T - P C R ,
whose representativeness is sample-dependent.
Probably, a negative aspect of xMAP™ technology is
represented by the use of enriched total RNA ( < 200 nt)
that requires higher amounts of starting material respect
to qRT-PCR. To avoid the enrichment step of < 200 nt
RNA molecules, we propose the use of LNA capture-
probe oligonucleotides that increase the affinity of the
oligonucleotide for its complementary RNA target lead-
ing to a significant enhance in stability and specificity of
the duplex.
We think that the technology we have developed could
be an alternative method to qRT-PCR for validating miR-
NAs expression data obtained with a large scale technol-
ogy such as microarray and it could have a wide
application in clinical, pharmaceutical, agricultural and
environmental studies.
Methods
Cell culture
Human alveolar RMS (ARMS) cell lines, positive for
PAX3-FKHR  translocation (RH4, RH30), negative for
PAX3-FKHR translocation (RH18) and human embryo-
nal RMS (ERMS) cells (RD, RH36, CCA, SMS-CTR) were
maintained in modified Eagle's medium (DMEM) con-
taining 10% fetal calf serum, penicillin (100 U/ml), and
streptomycin (100 μg/ml) (Invitrogen) at 37°C, 5% CO2 in
a humidified incubator.
The human RMS cell lines RH30 and RD were pur-
chased from ATCC (Manassas, VA); RH4 and RH18 were
a gift of Dr P .J. Houghton (St Jude Children's Hospital,
Figure 5 Second-strand synthesis by PCR reaction. A)Determina-
tion of the optimal PCR amplification cycle: the 2% agarose gel shows 
the amplification products of RH30 first-strand cDNA stopped at 15, 20, 
25 and 30 PCR cycles. B) Presence of specific miRNAs in the labeled 
cDNA population: the 2.25% agarose gel shows PCR amplification 
products of three specific miRNAs (miR-1, miR-206 and miR-450) per-
formed by using the sequence of each miRNA as forward primer, and 
the sequence for T7 promoter, which is common to all labeled mole-
cules, as reverse primer.Biscontin et al. BMC Molecular Biology 2010, 11:44
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Figure 6 Comparison of three different techniques used to define miRNA expression profiles in seven RMS cell lines. Expression levels of miR-
199a, miR-23a and miR-27a in seven RMS cell lines obtained with three methods (xMAP™, qRT-PCR and microarray) are represented. Mean value of 
expression and 95% confidence intervals are associated to each miRNA. The Figure also indicate, for each tested miRNAs, non-parametric Spearman 
correlations for the following paired comparisons: xMAP™ vs. microarray, xMAP™ vs. qRT-PCR and qRT-PCR vs. microarray.Biscontin et al. BMC Molecular Biology 2010, 11:44
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Memphis, TN); SMS-CTR, RH36, CCA were obtained
from Dr M. Tsokos (NCI, Bethesda, MD).
Isolation of small RNA molecules
Total RNA was prepared from seven cell lines of human
rhabdomyosarcoma using a modified TRIzol (Life Tech-
nologies Corporation, Carlsbad, CA, USA) protocol for
small RNA enrichment. A pellet of about 6 × 106 - 9 × 106
cells was dissolved in 1 ml of TRIzol and the supernatant,
containing total RNA, was purified by PureLink™ miRNA
Isolation Kit (Life Technologies Corporation) that was
specifically designed to enrich total RNA preparation for
< 200-nt RNA molecules. RNA quantity and quality were
assessed by Nanodrop (NanoDrop Technologies, Wilm-
ington, DE, USA) spectrophotometry and microelectro-
phoresis using Small RNA Nano LabChip by Agilent 2100
bioanalyzer (Agilent Technologies, Palo Alto, CA, USA)
respectively.
miRNA expression profiling and statistical analysis of data
microRNA expression profiling was carried out using the
"mirVana Probe Set V1" (Ambion) that is a collection of
about 400 amine-modified DNA oligonucleotides repre-
senting a panel of the human, mouse and rat microR-
NAome in the miRNA Registry (miRBase - Release 9).
The probes are 42-46 nucleotides (nt) long, with 18-24 nt
segment targeting a specific miRNA, and the remaining
sequence serving as spacer. We analyzed the expression
p r o f i l e s  o f  7  d i f f e r e n t  r h a b d o m y o s a r c o m a  c e l l  l i n e s :  3
ARMS (RH4, RH30, RH18) and 4 ERMS (RD, RH36,
CCA, SMS-CTR). The miRNA population from each cell
line was compared to a reference sample consisting of a
pool of the 7 total RNA samples mixed in equal amounts.
Two replicates of each experiment were performed using
different microarray slides, in which sample and refer-
ence RNAs, labeled either with Cy3 or Cy5 fluoro-
chromes, were crossed in both combinations (dye-
swapping procedure). miRNAs were labeled with the
mirVana Labeling Kit (Ambion) and amine-reactive dyes
(GE Healthcare) as recommended by the manufacturer's
protocol [45]. Normalization of expression levels of all
spot replicates was performed by MIDAW [50]. Principal
component analysis, cluster analysis and profile similarity
searching were performed with tMev software [51]. One
and two class Significance Analysis of Microarray (SAM)
allowed to identify differentially expressed miRNAs [52].
Capture probe and its coupling to microspheres
A sequence of 21-23 nt complementary for each tested
miRNAs (listed in the Table 1) was chosen as capture
probe and synthesized with 5'-amino linker and a C12
spacer (PRIMM, Milan, Italy). Capture-probe oligonucle-
otides were covalently linked to carboxylated fluoro-
chrome microspheres (Bio-Rad Laboratories, Hercules,
CA, USA) in water-soluble carbodiimide. Specifically, 1 ×
106 carboxylated microspheres were pelleted in a micro-
centrifuge for 5 minutes at 12,000×g and then superna-
tant was carefully removed. The dry microspheres were
dissolved in 20 μl of a buffer containing 0.1 M MES
(Sigma-Aldrich, St. Louis, MO, USA) at pH 4.5. The
amino-substituted capture probe was dissolved in molec-
ular biology grade water at a concentration of 100 μM
and 0.5 μl of the solution (containing 0.05 nmole of cap-
ture probe oligonucleotides) was added to the beads for
the coupling reaction. The coupling reaction was per-
formed by adding 2.5 μl of a freshly made solution of 10
mg/ml 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride (EDC) (Pierce, Thermo Scientific, Wilm-
ington, DE, USA) in molecular biology grade water. The
mixture of microspheres, capture probes, and EDC was
vortexed briefly and incubated at room temperature for
30 minutes in the dark. Occasionally, the reaction was
mixed by finger flicking the tube to keep the micro-
spheres in suspension. A second incubation steps was
done adding a freshly-made solution of 10 mg/mL EDC
in molecular biology grade water. After the coupling reac-
Table 2: Comparison of xMAP™ and qRT-PCR techniques
xMAP™ qRT-PCR
< 200 nt RNA molecules enrichment YES NO
RT step YES YES
Amplification YES YES
Endogenous control NO YES
Control spike YES NO
Multiplexing YES NO
Liquid-phase hybridization YES NO
No. of measures 100 1
Custom-tailored assay YES NO
Cost Low HighBiscontin et al. BMC Molecular Biology 2010, 11:44
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tion, 500 μl of 0.02% Tween 20 (Sigma-Aldrich) was
added to the microspheres. The solution was mixed well
by vortex and centrifuged for 6 minutes at 12,000×g. The
supernatant containing free-capture-probe oligonucle-
otides and excess EDC was carefully removed. The cou-
pled microspheres were washed in 500 μl of 0.1% SDS
(Sigma-Aldrich) by vortex and centrifuged for 5 minutes
at 12,000×g. Finally, the supernatant was removed and
the capture-probe conjugated microspheres were resus-
pended in 20 μl of TE pH 8.0 and stored at 4°C in a dark
box (stable for at least 6 months). The microspheres were
diluted in TE buffer and counted using a Bürker chamber
under the microscope at 100× magnification.
miRNA labeling
At the beginning, 1 μg of small RNA molecules (< 200-nt)
and 200 pg of a synthetic pre-labeling control RNA (5'-
UCUUAGUCUUGAUUGUGGCAAUG-3', PRIMM)
were mixed in order to control target preparation effi-
ciency and to normalize expression data. The mixture
was polyadenylated using Poly(A) Tailing Kit (Ambion)
according to the manufactures' instructions. The reaction
was precipitated with NaOAc 3 M pH 5.5 (1/10 volume)
and absolute ethanol (4 volumes) overnight at -20°C. The
polyadenylated RNA molecules were resuspended in 15
μl of H2O RNase free and then volume was reduced to 3.2
μl by vacuum (VR-1, Heto-Holten, Denmark). miRNAs
labeling was performed by mRAP modified protocol in
which miRNA-derived cDNAs were flanked by synthe-
sized oligomers at each end. The SMART (switching
mechanism at the 5'-end of RNA templates of reverse
transcriptase) oligo sequence (SMART-16attB1-T3: 5'-
TACAAAAAAGCAGGCTAATTAACCCTCAC-
TAAAggg-3') and the overhang of the oligo-dT15-T7
primer (5'-GTGAATTGTTAATACGACTCACTATAG-
GCGC [dT]15N-3') were used for first strand synthesis.
First strand cDNA synthesis was performed from 500 ng
of small RNA in a 10 μl reaction. Then, the reaction was
diluted 1:2 and incubated at 72°C for 7 min. Second
strand reaction mix was added to 3.0 μl of diluted first
strand cDNA to give a final concentration of 1X BD
Advantage 2 PCR reaction buffer (Clontech Laboratories,
Mountain View, CA, USA), 0.2 mM dNTPs, 100 nM
primers (T3-biotinylated forward primer: 5' - biotAAT-
TAACCCTCACTAAAGGG-3' and T7 reverse primer:
5'- TAATACGACTCACTATAGG-3') and 1X of Advan-
tage 2 DNA polymerase mix (Clontech Laboratories) in a
total volume of 25 μl. This second strand reaction mix-
ture was incubated for 22 cycles of the following steps: 15
sec 95°C, 20 sec 51°C and 20 sec 72°C. Only those ss
cDNAs having a SMART anchor sequence at the 5'-end
were used as template and exponentially amplified. The
second strand reaction was precipitated in sodium ace-
tate-ethanol solution and dissolved in 11 μl TE buffer pH
8.0 (10 mM TrisHCl pH 8.0, 1 mM EDTA). Biotinylated
cDNA quantity was assessed by Nanodrop spectropho-
tometer (Nanodrop Technologies) and stored at -20°C
until hybridization with microspheres. Labelled target
produced by a single PCR reaction was sufficient for two
hybridization reactions.
Hybridization of targets to capture probes coupled to 
microspheres
The microspheres of each probe set were resuspended by
vortexing for approximately 20 seconds. A microsphere
mixture was prepared by diluting coupled stocks to 150
microspheres of each set/μl in 1.5× TMAC Hybridization
Buffer (5 M tetramethylammonium chloride, 0.15%
Sarkosyl; 75 mM Tris-HCl pH 8.0; and 6 mM EDTA, pH
8.0), followed by vortex mixing for approximately 20 sec-
onds. Two μg of biotinylated DNA target in 17 μL of TE
buffer pH 8.0 was added to 33 μl of microsphere mixture
(approximately 5,000 beads per color) in the wells of a 96-
well plate. 17 μl of TE buffer pH 8.0 were added to back-
ground wells. Each well reaction was mixed gently by
pipetting up and down several times and the labeled
DNA was denatured by heating at 95-100°C for 3 min.
The hybridization mixture was incubated at 48°C for 17
h, covering the plate to prevent evaporation, in a Eppen-
dorf microplate incubator with shaking speed of 700 rpm.
After incubation, the hybridization mixture was spun
down for 3 min at 3,000×g to pellet the microspheres.
Supernatant was carefully removed with a pipette with-
out disturbing the microspheres. During centrifugation,
fresh reporter mix was prepared by diluting streptavidin-
conjugated R-phycoerythrin (Invitrogen) to 3 mg/ml in
1× TMAC Hybridization Buffer and 75 μl of reporter mix
were added to the microspheres. The solution was gently
mixed by pipetting and incubated in the dark at 48°C for
15 minutes in a Eppendorf microplate incubator. 50 μl of
each sample were transferred to a Multiscreen HTS plate
(Millipore) and analyzed on the BioPlex™ (Luminex® 100™,
BioRad) machine at hybridization temperature.
Bead-based detection
Each set of microspheres was distinguished by assigned
colour code (different percentage of red and orange)
inside the microspheres. In our experiments we have
used four different probe sets (regions: 1, 21, 51 e 57).
The fluorescence associated to the surface of each bead,
corresponding to the amounts of bound miRNAs, was
detected and measured by the laser detector. The Bio-
Plex™ (Luminex®  100™, Bio-Rad Laboratories) system
detects fluorescent dyes with an excitation wavelength of
-532 nm and emission wavelength -580 nm. For each
experiment, 100 events of each subset of microspheres
were analyzed on the Bio-Plex™ system to obtain aBiscontin et al. BMC Molecular Biology 2010, 11:44
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median fluorescence intensity value (MFI) that was rep-
resentative of the whole population of each set of beads.
Computational analyses (data processing and quality 
control)
To eliminate bead-specific background, the reading of
every bead for every samples was first processed by sub-
tracting the average readings of that particular bead in
the absence of target miRNAs. Samples with median flu-
orescence intensity values smaller than background sig-
nals were removed. Every samples was assayed in three
wells. Each of the three wells contained 4 probes: miR-
23a, miR-27a, miR-199a and one pre-labeling control
(Spike-18). Expression data were scaled according to the
pre-labeling control in order to normalize readings from
different probe/bead sets for the same sample and to nor-
malize for the labeling efficiency. Technical replicate
samples for each probe were summarized by their mean
profile and expression data (test/control) were log2 trans-
formed. The error associated to each probe is obtained by
quadratic propagation from standard deviation.
qRT-PCR TaqMan
TaqMan® MicroRNA Assays incorporate a target-specific
stem-loop, reverse transcription primer. The stem-loop
structure provides specificity only for the mature miRNA
target and forms a RT primer/mature miRNA-chimera
that extends the 5'-end of the miRNA. The resulting lon-
ger RT amplicon presents a template amenable to stan-
dard real-time PCR using TaqMan Assays [22]. In brief,
according to the manufacture's instructions (Applied Bio-
systems), each 15 μl RT reaction contained purified 10 ng
of total RNA, 3.0 μl of 5× stem-loop RT primer, 1× RT
buffer, 0.25 mM each of dNTPs, 50 U MultiScribe™
reverse transcriptase and 3.8 U RNase inhibitor. The
reactions were incubated in a Mastercycler EP gradient S
(Eppendorf) in 0.2 ml PCR tubes for 30 min at 16°C, 30
min at 42°C, followed by 5 min at 85°C, and then held at
4°C. RT products were diluted two times with H2O prior
to setting up PCR reaction. Each real-time PCR for each
miRNA assay (10 μl volume) was carried out in triplicate,
and each 10 μl reaction mixture included 1 μl of diluted
RT product, 5 μl of 2 × TaqMan® Universal PCR Master
Mix and 0.5 μl of 20× TaqMan® MicroRNA Assay. The
reaction was incubated in a 7500 Real-Time PCR System
(Applied Biosystems) in 96- well plates at 95°C for 10 min,
followed by 40 cycles of the following steps: 95°C for 15
sec and 60°C for 1 min. The threshold cycle (CT) is
defined as the fractional cycle number at which the fluo-
rescence exceeds the fixed threshold of 0.2. To evaluate
differences in miRNA expression, a relative quantification
method was chosen where the expression of the miRNA
target is standardized by a non-regulated small non-cod-
ing RNA used as reference.
Consequently, three replicates of each sample and
endogenous control were amplified. U6B small nuclear
(RNU6B) was used as endogenous control because the
level of this small RNA remains essentially constant from
sample to sample. To calculate the relative expression
ratio, the 2-Δ ΔCt (RQ, relative quantification) method
implemented in the 7500 Real Time PCR System software
[53] was used. This method determines the change in
expression of a nucleic acid sequence (target) in a test
sample relative to the same sequence in a calibrator sam-
ple.
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